Line 119: | Line 119: | ||
margin-bottom: 210px; | margin-bottom: 210px; | ||
padding: 0; | padding: 0; | ||
− | |||
− | |||
− | |||
− | |||
} | } | ||
Line 265: | Line 261: | ||
<div class="section-content"> | <div class="section-content"> | ||
<h2 style="text-align: left; color: #44414d">The ideal medicine is not a perfect treatment . . .</h2> | <h2 style="text-align: left; color: #44414d">The ideal medicine is not a perfect treatment . . .</h2> | ||
− | |||
<br> | <br> | ||
<br> | <br> | ||
Line 277: | Line 272: | ||
towards numerous tracks of scientific | towards numerous tracks of scientific | ||
development.</h2> | development.</h2> | ||
− | |||
<br> | <br> | ||
<br> | <br> | ||
Line 290: | Line 284: | ||
<h2 style="text-align: left; color: #44414d">Despite the potential for establishing an ideal medicine, | <h2 style="text-align: left; color: #44414d">Despite the potential for establishing an ideal medicine, | ||
there are still numerous challenges.</h2> | there are still numerous challenges.</h2> | ||
− | |||
<br> | <br> | ||
<br> | <br> | ||
Line 306: | Line 299: | ||
<div class="section-content"> | <div class="section-content"> | ||
<h2 style="text-align: center; color: #44414d">How do we overcome these problems?</h2> | <h2 style="text-align: center; color: #44414d">How do we overcome these problems?</h2> | ||
− | |||
<br> | <br> | ||
<br> | <br> | ||
<h2 style="text-align: center; color: #44414d" class="home-title">SNIP | <h2 style="text-align: center; color: #44414d" class="home-title">SNIP | ||
<span style="color: #7ccfb8">EQUIP</span> FLIP</h2> | <span style="color: #7ccfb8">EQUIP</span> FLIP</h2> | ||
− | |||
<br> | <br> | ||
<h2 style="text-align: center; color: #44414d">The system that allows for the integration and | <h2 style="text-align: center; color: #44414d">The system that allows for the integration and | ||
Line 323: | Line 314: | ||
allows for the creation of eukaryotic cell lines via stable integration and expression of exogenous | allows for the creation of eukaryotic cell lines via stable integration and expression of exogenous | ||
genes.</h2> | genes.</h2> | ||
− | |||
<br> | <br> | ||
<br> | <br> | ||
Line 336: | Line 326: | ||
capabilities of FLP recombinase and beta resolvase, gene integration into eukaryotic genomes becomes a | capabilities of FLP recombinase and beta resolvase, gene integration into eukaryotic genomes becomes a | ||
simple process of Snip, Equip, Flip.</h2> | simple process of Snip, Equip, Flip.</h2> | ||
− | |||
<br> | <br> | ||
<br> | <br> |
Revision as of 03:04, 18 October 2018
SNIP EQUIP FLIP
Advancements in genetic modification have opened avenues towards numerous tracks of scientific development.
In particular, the demand for permanent health solutions has sparked massive interest in gene therapy.
Despite the potential for establishing an ideal medicine, there are still numerous challenges.
The selection of an integration target site, methodology pertaining to gene delivery, and maintenance of gene expression currently limit the potential for gene therapy to become common practice.
How do we overcome these problems?
SNIP EQUIP FLIP
The system that allows for the integration and maintenance of large-scale genetic constructs in eukaryotic systems.
University of Calgary’s Snip, Equip, Flip aims to overcome the aforementioned obstacles. This system allows for the creation of eukaryotic cell lines via stable integration and expression of exogenous genes.
Snip, Equip, Flip is a simple and reliable method that can be used by experienced and entrant researchers alike that can lead to a vast array of scientific discoveries.
By complementing the specificity of targeting that CRISPR/Cas9 offers with the much larger integration capabilities of FLP recombinase and beta resolvase, gene integration into eukaryotic genomes becomes a simple process of Snip, Equip, Flip.
The expression of integrated genes is then protected and maintained over time by adding flanking chromatin modifying elements.
Use arrow keys
or scroll
or scroll